Think of Leqvio as a Niche Med for Lowering LDL
Rx Leqvio (inclisiran) will be the first “small interfering RNA” therapy for lowering cholesterol.
This injectable works at a different step in the same pathway as the PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab).
Leqvio prevents formation of the PCSK9 protein...Praluent and Repatha prevent PCSK9 binding. All of them increase LDL receptors in the liver and clearing of LDL cholesterol from the blood.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote